Immunologic Deficiency Syndromes clinical trials
The registry lists 204 studies for Immunologic Deficiency Syndromes across more than 10 countries. 50 are recruiting or about to start. 76 of them are mainly about Immunologic Deficiency Syndromes (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 20 narrower conditions too, such as HIV Infections: 7,662 studies, 716 open.
Get an email when these change. Save the Immunologic Deficiency Syndromes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (32) · National Cancer Institute (NCI) (13) · Children's Hospital of Philadelphia (7) · Sumitomo Pharma Switzerland GmbH (6) · University of California, San Francisco (4) · Grifols Therapeutics LLC (3) · Fred Hutchinson Cancer Center (3) · Masonic Cancer Center, University of Minnesota (3)
What is being tested here
Drugs under test in Immunologic Deficiency Syndromes studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Alkylating agents 3 open · Antimetabolites 1 open · Calcineurin inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies · Children's Hospital of Philadelphia
- Nov 2026Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy · Washington University School of Medicine
- Dec 2026Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients. · Centre Hospitalier Régional d'Orléans
- Dec 2026OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial · ANRS, Emerging Infectious Diseases
- Jan 2027Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC · Children's Hospital of Philadelphia
- Jan 2027Allergy and Immunology Natural History Study · Columbia University
- Feb 2027Project Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa · University of Maryland, College Park
- Mar 2027Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis · National Institute of Allergy and Infectious Diseases (NIAID)
- Jun 2027A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases · Pierre Fabre Medicament
- Jun 2027Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) · Masonic Cancer Center, University of Minnesota
Who these studies take
Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger. 30 (70%) take children under 18. 0 (0%) are for women only and 1 (2%) for men only; 10 (23%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 24 (56%) | 25 (58%) |
| 18 | 39 (91%) | 40 (93%) |
| 30 | 34 (79%) | 35 (81%) |
| 40 | 33 (77%) | 34 (79%) |
| 50 | 32 (74%) | 33 (77%) |
| 65 | 31 (72%) | 32 (74%) |
| 75 | 30 (70%) | 31 (72%) |
| 85 | 28 (65%) | 28 (65%) |
Across all 204 studies, recruiting or not: 47% stop at 75 or younger and 35% at 65; 66% take children; <1% are for women only and 5% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Immunologic Deficiency Syndromes studies take
Of 38 observational studies under Immunologic Deficiency Syndromes, half reached primary completion within 77 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 152 mo9–159 · 21 studies | — | — |
| Observational | 77 mo53–… · 38 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Results posted1
- Immune Disorder HSCT ProtocolOct 27, 2026NCT01821781
Studies
Recruiting first, then most recently updated. Showing 50 of 204. Browse all 204 → or search them.
- Pathogenesis and Genetics of Disseminated or Refractory CoccidioidomycosisRecruitingNCT021902661 country
- The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known ImmunocompromiseRecruitingNCT010117121 country
- Natural History of Noncirrhotic Portal HypertensionRecruitingNCT024177401 country
- Apheresis of Patients With ImmunodeficiencyRecruitingNCT012120551 country
- Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)RecruitingNCT000061501 country
- Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ LymphocytopeniaRecruitingNCT008672691 country
- Detection and Characterization of Host Defense DefectsRecruitingNCT000013551 country
- Genetic Analysis of Immune DisordersRecruitingNCT000014671 country
- Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without ThymectomyRecruitingNCT074162011 country
- Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIVRecruitingNCT000012811 country
- Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationNCT07775313Phase 1/21 country
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy TrialRecruitingNCT05587894Phase 23 countries
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromeRecruitingNCT05027945Phase 21 country
- Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseRecruitingNCT033008301 country
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingNCT01861106Phase 21 country
- Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating MutationsNot yet recruitingNCT07670156Phase 1/21 country
- Toxin Exposure and Immune Dysregulation in Non-Hodgkin LymphomaRecruitingNCT076525801 country
- Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical VentilationRecruitingNCT05405491Not applicable1 country
- R-MVST Cells for Treatment of Viral Infections in Children and Young AdultsRecruitingNCT06926894Phase 11 country
- Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSCAvailableNCT031455451 country
- Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)RecruitingNCT01666080Not applicable1 country
- Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.RecruitingNCT064741691 country
- Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular TherapyRecruitingNCT06689800Not applicable1 country
- Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)Enrolling by invitationNCT034786701 country
- Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary ImmunodeficienciesRecruitingNCT027358241 country
- Vaccine-induced Immunity in Immunocompromised PatientsRecruitingNCT066125151 country
- Impact of Thymectomy on Immunity in Infants After Cardiac SurgeryRecruitingNCT07019857Not applicable1 country
- Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTRecruitingNCT06839456Phase 1/21 country
- Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated ColitisRecruitingNCT05333471Phase 1/21 country
- Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DMRecruitingNCT03835312Not applicable1 country
- Expanded Access Protocol Using CD3+/CD19+ Depleted PBSCRecruitingNCT02356653Early Phase 11 country
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 PatientsRecruitingNCT07406217Phase 21 country
- Biologics And Clinical Immunology Cohort at SinaiRecruitingNCT047843641 country
- Allergy and Immunology Natural History StudyRecruitingNCT055844881 country
- V-IMMUNE: A Novel Immunoglobulin Therapy for ImmunodeficiencyRecruitingNCT06954441Phase 31 country
- Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University HospitalRecruitingNCT072995001 country
- Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood TransplantsAvailableNCT018813341 country
- Clozapine-related Immunodeficiency in Parkinsons DiseaseRecruitingNCT06634641Phase 41 country
- Umbilical Cord Blood Transplantation From Unrelated DonorsRecruitingNCT030168061 country
- Assessing Patient Preference for Infusion SystemsNot yet recruitingNCT07189013Not applicable1 country
- Shwachman-Diamond Syndrome Global Patient Survey and Partnering PlatformRecruitingNCT069999541 country
- X-linked Moesin Associated ImmunodeficiencyRecruitingNCT062783376 countries
- Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older AdultsRecruitingNCT05421325Phase 21 country
- Immune Homeostasis in Sepsis and Septic ShockRecruitingNCT044489511 country
- Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious RiskRecruitingNCT06475469Not applicable1 country
- Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide RibosideNot yet recruitingNCT06324877Not applicable1 country
- Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care UnitRecruitingNCT049909081 country
- Immunodeficiency and Cancer: Identification of Congenital Immune System Defects Underlying Paediatric LymphomasRecruitingNCT06332196Not applicable1 country
- SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATIONRecruitingNCT062489571 country
- Vaccination for Children of H&O and Their ParentsRecruitingNCT03373656Not applicable1 country